期刊
CLINICAL INFECTIOUS DISEASES
卷 52, 期 -, 页码 S312-S325出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir046
关键词
-
资金
- US Department of Defense [W81XWH-08-1-0477]
- Food and Drug Administration
- Infectious Diseases Society of America
- AstraZeneca Pharmaceuticals
- Bio Merieux, Inc.
- Cepheid
- Gilead Sciences
- Intelligent MDX, Inc.
- Inverness Medical Innovations
- Roche Molecular Systems
- GenProbe/Prodesse
- Luminex Molecular Diagnostics
- Diagnostic Hybrids
- 3M Molecular Diagnostics
The rapid, sensitive, and specific identification of the microbial etiological characteristics of respiratory tract infections enhances the appropriate use of both antibiotics and antiviral agents and reduces the risk of nosocomial transmission. This article reviews the current nucleic acid amplification tests approved by the U.S. Food and Drug Administration (FDA) for the detection of respiratory pathogens. In addition, Emergency Use Authorization tests for the detection of 2009 influenza A H1N1 are discussed. The advantages and limitations of the current FDA-approved/cleared tests are reviewed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据